Monopar Therapeutics: COO Andrew Cittadine exercised 4,384 shares

What happened Andrew Cittadine, chief operating officer, received 4,384 shares on Sep 30, 2026 via exercise or conversion of a derivative (reported as code M). The filing shows 1,944 shares were surrendered to the issuer to pay withholding tax at $79.67 per share for a total of $154,878 (code F). The filing also lists a derivative disposition of 4,384 shares at $0.00 (code M).

Key details

• Transaction date: Sep 30, 2026. Filing date: Oct 2, 2026 (filed within two business days).
• Prices reported: 4,384 shares at N/A (acquisition entry), 1,944 shares withheld at $79.67 for $154,878, and 4,384 shares disposed at $0.00 (derivative).
• Shares owned after the transaction: not reported in the provided filing details.
• Relevant footnotes: F1 indicates shares were acquired on vesting and settlement of restricted stock units; F2 indicates shares were withheld to pay applicable withholding tax; F3, F4 and F5 describe prior restricted stock unit grants and vesting schedules that underlie the transactions.
• Transaction codes: M = exercise or conversion of derivative; F = payment of exercise price or tax liability (withholding).

Why it may matter The filing describes vesting/settlement of restricted stock units and withholding of shares to cover taxes (a non-cash tax withholding). A filing does not show why the insider traded or why the company acted.